Literature DB >> 11311473

Treatment-induced neoangiogenesis in cerebral arteriovenous malformations.

U Sure1, N Butz, A M Siegel, H D Mennel, S Bien, H Bertalanffy.   

Abstract

We investigated the angiogenetic and proliferative activity of the endothelium of 30 consecutive surgical cases of AVM treated at our institution by immunohistochemical detection of the PCNA, MIB-1, Flk-1 and VEGF antibodies. Endothelial positive immunostaining was observed in 87% of the cases for PCNA, in 20% for MIB-1, and in 80% for Flk-1. Of 22 individuals treated with incomplete embolization prior to surgery, 17 showed an expression of VEGF (77%), but only two of the eight patients (25%) who were treated without prior embolization exhibited such an immunoreaction (P=0.0086). The proliferation and growth of cerebral AVMs is documented by endothelial expression of PCNA and MIB-1. The statistically significantly higher expression of VEGF in partially obliterated (embolized) AVMs is most likely caused by transient regional hypoxia within the AVM nidus that mediates neoangiogensis. It points out the clinical relevance of a complete occlusion in order to avoid neovascularization associated with subsequent morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311473     DOI: 10.1016/s0303-8467(01)00112-3

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  17 in total

Review 1.  Pathophysiology and treatment of brain AVMs.

Authors:  Ulrich Grzyska; Jens Fiehler
Journal:  Klin Neuroradiol       Date:  2009-05-15

2.  PWI-MRI and contrast extravasation in brain AVM help to estimate angiogenic activity.

Authors:  Guillaume Saliou; Timo Krings; Dik R Rutgers; Frederique Toulgoat; Augustin Ozanne; Pierre Lasjaunias; Denis Ducreux
Journal:  Neuroradiology       Date:  2011-05-12       Impact factor: 2.804

3.  Permanent inflammatory effect of N-butylcyanoacrylate on vascular wall immunohistochemical analysis.

Authors:  J Talan-Hranilović; T Rumboldt; M Vucic; Z Rumboldt; V Beros; V Tonković; V Lupret
Journal:  Interv Neuroradiol       Date:  2004-10-22       Impact factor: 1.610

4.  Seizure predictors and outcome after Onyx embolization in patients with brain arteriovenous malformations.

Authors:  Baorui Zhang; Xin Feng; Fei Peng; Luyao Wang; Er Kang Guo; Yupeng Zhang; Peng Liu; Zhongxue Wu; Aihua Liu
Journal:  Interv Neuroradiol       Date:  2018-09-30       Impact factor: 1.610

5.  Endothelial signaling and the molecular basis of arteriovenous malformation.

Authors:  Deepak Atri; Bruno Larrivée; Anne Eichmann; Michael Simons
Journal:  Cell Mol Life Sci       Date:  2013-09-28       Impact factor: 9.261

6.  An early venous abnormality: a potential cause of arteriovenous malformation recurrence.

Authors:  David Weingarten; Sean Pakbaz; Aaron Cho; Hoi Sang U
Journal:  BMJ Case Rep       Date:  2012-09-11

7.  Biological activity of paediatric cerebral cavernomas: an immunohistochemical study of 28 patients.

Authors:  Wuttipong Tirakotai; Sandra Fremann; Niels Soerensen; Wolfgang Roggendorf; Adrian M Siegel; Hans Dieter Mennel; Yuan Zhu; Helmut Bertalanffy; Ulrich Sure
Journal:  Childs Nerv Syst       Date:  2006-02-18       Impact factor: 1.475

8.  Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation.

Authors:  Qi Hao; Hua Su; Douglas A Marchuk; Radoslaw Rola; Yongqiang Wang; Weizhong Liu; William L Young; Guo-Yuan Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-03       Impact factor: 4.733

Review 9.  [Treatment options for arteriovenous malformations].

Authors:  M-A Weber; F Ahlhelm; M Essig; W Reith; B Stieltjes
Journal:  Radiologe       Date:  2007-10       Impact factor: 0.635

10.  Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain.

Authors:  Espen J Walker; Hua Su; Fanxia Shen; Vincent Degos; Gregory Amend; Kristine Jun; William L Young
Journal:  Stroke       Date:  2012-05-08       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.